Clinical Trial Update: Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating a senolytic agent to enhance benefits of platelet-rich plasma and losartan for femoroacetabular impingement.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Femoroacetabular Impingement

Drugs mentioned

• Losartan (losartan)
• Platelet-rich plasma (platelet-rich plasma)
• Senolytic agent

Snippet

Sponsor: Steadman Philippon Research Institute | Conditions: Femoroacetabular Impingement | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING